Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: final results of the PROBone Registry Study

An analysis of patient-reported complaints and limitations caused by bone metastases (BM) related to breast (n = 310) and prostate cancer (n = 176) showed that 79.7% and 59.7% of those with breast and prostate cancer, respectively, began bone-targeted agent (BTA) therapy within 3 months after diagnosis of BM, consistent with current guideline recommendations. Using the FACT-BP score, patients reported constant improvement in general and bone pain across the first months after beginning the BTA and stabilizing after that.